The brain and spine tumor programs at NewYork-Presbyterian integrate multiple disciplines to provide comprehensive treatment strategies that include minimally invasive surgery, radiation therapies, and intra-arterial chemotherapy.

A family history of Alzheimer’s disease has been the driving force for a NewYork-Presbyterian/Weill Cornell physician on a mission to intervene before the disease takes hold.

Scott A. Small believes the key in leading scientists down a new pathway for drug discovery may be in targeting a biological mechanism in the cell called retromer endosomal dysfunction.

In October 2017, renowned neuro-oncologist Howard A. Fine, was awarded a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer research.

At the Eleanor and Lou Gehrig ALS Center at NewYork-Presbyterian/Columbia, clinicians and scientists are leading efforts to combat amyotrophic lateral sclerosis and other motor neuron diseases.

A NewYork-Presbyterian/Weill Cornell neurosurgeon is redefining treatment of essential tremor, as the first in New York to offer high-intensity focused ultrasound to treat the brain disorder.

Over the past three decades, Dr. Manikkam Suthanthiran and his colleagues at NewYork-Presbyterian/Weill Cornell is responsible for much of the progress in kidney transplantation.

NewYork-Presbyterian/Columbia, a Kidney Precision Medicine Project recruitment site, is working to understand the cell types that are specific to kidney injury and can be targeted with new therapeutic agents.